A roadmap for establishing institutional readiness for cellular therapies targeting solid tumours and autoimmune diseases

npj Precision Oncology 2026 Open access

Read full text
Authors: Sarah Childs, Dávid Ma, Elizabeth Houghton, Rasha Cosman, Jennifer Massey, Venessa Chin, Valerie Valencia, Aaron O'Grady, Simone Kay Jensen, Amanda McLaughlin, Simon Goodwin, Helen Tao
+21 more Barbara Withers, Callie Noakes, Annabel Horne, Paul Preisz, Jessica Boyd, Dion Forstner, Anthony Rodrigues, Geeta Sandhu, Karim Ibrahim, Chloe Martin, Benjamin Kwan, Nicolas De Luca, Hergen Buscher, PH Cunningham, Anthony M. Joshua, Laila Girgis, Ben Tran, Jayesh Desai, Simon James Harrison, John Moore, Jia Liu
DOI: 10.1038/s41698-026-01462-6
Cited by: 1
References: 40

Abstract

Adoptive cellular therapies have revolutionised treatment of haematological malignancies and demonstrate potential in solid tumours and autoimmune disease. Real-world implementation remains limited by biological, logistical, and manufacturing barriers, restricting global uptake despite a rapidly expanding clinical trial portfolio. Effective implementation requires national and institutional readiness, multidisciplinary collaboration, scalable manufacturing, and robust infrastructure. Efforts should prioritise decentralised and "off the shelf" platforms, integrated referral networks, and AI-assisted patient management to support safe, equitable and efficient global delivery.

Fields of Study & Subjects

CAR-T cell therapy research Biomedical Ethics and Regulation Monoclonal and Polyclonal Antibodies Research

Publication details

Journal / source
npj Precision Oncology
Publisher
Springer Science and Business Media LLC
Volume
10
Issue
1
Publication date
7 May 2026
Language
EN